Starboard Value has taken a stake in Becton Dickinson (BDX) and is pushing the medical technology company to sell its life sciences division, The Financial Times’ Oliver Barnes and Amelia Pollard report. According to people familiar with the matter, the activist investor has met the company’s management team and sent a letter to the board urging Becton Dickinson to sell or spin off the unit. The size of Starboard’s stake is unclear.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson approves additional 10M shares repurchase program
- Becton Dickinson price target raised to $280 from $275 at Piper Sandler
- Becton Dickinson, Biosero announce framework collaboration agreement
- Becton Dickinson price target lowered to $278 from $312 at Barclays
- Becton Dickinson announces additional investments in manufacturing